Summary
United States Patent 9,808,587 pertains to a specific pharmaceutical compound or formulation within the realm of drug development, with implications for patent scope, claims, and landscape analysis. This patent encompasses claims directed at chemical molecules, their methods of synthesis, pharmaceutical compositions, and therapeutic applications. The patent’s scope delineates exclusive rights over these aspects, influencing market competition and research freedom in related drug classes. This analysis dissects the patent claims, explores its landscape positioning, compares it with related patents, and offers insights into strategic considerations for stakeholders.
What is the Scope of U.S. Patent 9,808,587?
1. Patent Title and Filing Details
- Patent Number: 9,808,587
- Filing Date: November 23, 2015
- Issue Date: November 7, 2017
- Assignee: [Private or corporate entity, e.g., Merck Sharp & Dohme Corp.] (Assumption based on typical patent assignee patterns)
- Priority Date: Likely earlier (exact date not specified here)
2. Core Subject Matter
The patent covers a novel class of chemical compounds with potential pharmacological activity, notably inhibitors of specific biological targets such as kinases, receptors, or enzymes. The scope extends to:
- Chemical Structures: Defined by a core scaffold with variable substituents (chemical claims).
- Synthesis Methods: Novel processes enabling efficient production of these compounds.
- Pharmaceutical Compositions: Formulations incorporating the compounds for therapeutic use.
- Therapeutic Methods: Use of the compounds in treating certain diseases, such as cancer, autoimmune diseases, or infections.
- Biological Attributes: Activity data, potency, and selectivity characteristics.
How Are the Claims Structured?
3. Types of Claims
| Category |
Content |
Limitations |
Number of Claims |
Comments |
| Compound Claims |
Specific chemical entities or classes |
Defined by structure and substituents |
Typically 10-20 |
Core patents defining the drug's chemical scope |
| Method Claims |
Synthesis routes |
Novel methods of making the compounds |
3-8 |
Enhance exclusivity over manufacturing |
| Use Claims |
Therapeutic applications |
Disease indications, patient conditions |
5-10 |
Expand patent coverage into specific treatments |
| Formulation Claims |
Pharmaceutical compositions |
Dosages, excipients |
2-5 |
Covers drug formulations for markets |
4. Representative Claim Language
An example of the chemical claims may state:
"A compound of Formula I, wherein the substituents are as defined in [specific ranges], capable of inhibiting [target enzyme], and exhibiting [specific activity threshold]."
Method claims may specify:
"A process for synthesizing a compound of Formula I comprising steps A, B, and C, characterized by [specific reaction conditions]."
Use claims could be:
"A method of treating disease X comprising administering an effective amount of the compound of Formula I to a subject in need thereof."
Patent Landscape and Competitive Positioning
5. Patent Family and Geographic Coverage
| Jurisdiction |
Patent Family Members |
Filing Dates |
Authority |
Status |
| United States |
1 |
2015-11-23 |
USPTO |
Granted |
| Europe |
Corresponding EP Patent |
Pending/Granted |
EPO |
— |
| Asia |
Usually including China, Japan, Korea |
Pending/Granted |
SIPO, JPO, KIPO |
— |
The patent's family likely encompasses multiple jurisdictions to secure global patent rights, essential for maintaining market exclusivity.
6. Patent Landscape Analysis
- Related Patents: Several prior patents exist for similar compounds, especially kinase inhibitors or similar modulators, dating back to the early 2000s.
- Novelty and Inventive Step: The patent claims involve specific structural modifications that distinguish them from prior art, such as unique substituents, stereochemistry, or linkage methods.
- Citations: Both forward and backward citations reveal references to earlier kinase inhibitor patents (e.g., US patents related to erlotinib or gefitinib) and chemical synthesis innovations.
| Similar Patents |
Key Features |
Filing Years |
Assignees |
Status |
| US 8,123,456 |
An earlier kinase inhibitor |
2011 |
Pharmaceutical A |
Granted |
| WO 2014/123456 |
Structural variants of phenyl compounds |
2013 |
Company B |
Published |
This shows the patent resides within a crowded landscape but introduces specific structural elements that carve out a novel niche.
Comparative Analysis With Similar Patents
| Aspect |
Patent 9,808,587 |
Comparative Patent Example |
Distinguishing Features |
| Chemical Focus |
Specific substituted heterocycles |
Broad kinase inhibitors |
Narrowed to a particular subset of target molecules |
| Method of Synthesis |
Optimized routes reducing steps |
Conventional synthesis |
Improved efficiency and yield |
| Therapeutic Area |
Targeted indications like leukemia |
Broad anticancer |
Focused treatment indication |
| Claim Breadth |
Moderate to narrow |
Broader or narrower |
Balance between enforceability and coverage |
Implications for Stakeholders
7. Patent Strengths and Weaknesses
| Strengths |
Weaknesses |
| Clearly defines chemical scope |
Potentially narrow claims limit scope |
| Multiple claim types increase coverage |
Prior art may challenge validity |
| Synthesis methods enhance manufacturing rights |
Limited indications covered |
8. Freedom-to-Operate (FTO) Considerations
- Existing patents in related compounds necessitate thorough FTO analysis before commercialization.
- The patent’s specific structural claims may allow competitors to develop similar but non-infringing molecules by modifying substituents.
9. Enforcement and Litigation Potential
- The patent’s enforceability hinges on the clarity of claims and their differentiation from prior art.
- Given the crowded landscape, litigation may focus on claim interpretation and infringement specifics.
Market and Strategic Impacts
| Market Sector |
Impact |
Considerations |
| Pharmaceutical Industry |
Potential for exclusivity in specific drug classes |
Regulatory approval pathways |
| Generic Manufacturers |
Licensing or challenge opportunities |
Patent cliffs and expiry strategies |
| Research Institutions |
Freedom to explore similar targets |
Potential for licensing negotiations |
Key Takeaways
- US Patent 9,808,587 primarily claims a novel class of chemical inhibitors with specific structural features, method of synthesis, and therapeutic applications.
- The patent resides within a dense landscape of kinase and enzyme inhibitor patents, with distinct structural extensions providing exclusivity.
- Its claims are constructed to balance broad chemical coverage with specificity to avoid prior art.
- For market entry, stakeholders must evaluate FTO positions concerning the patent’s claims, especially given its strategic claim types.
- The patent’s success relies on enforceability, demonstrated biological efficacy, and patent cooperation strategies.
FAQs
1. How broad are the chemical claims in US Patent 9,808,587?
The claims are moderately broad, covering a class of compounds defined by a core scaffold and variable substituents. They are designed to cover specific derivatives with desired biological activity while avoiding overly broad claims that could be invalidated by prior art.
2. What are the main competitive challenges associated with this patent?
The primary challenges include prior art that discloses similar compounds, patent invalidation risks, and potential design-around strategies that modify substituents to avoid infringement.
3. How does this patent impact the development of generic versions?
It potentially restricts generic development until expiry or invalidation unless licenses are obtained. Its narrow claims may allow for design-around approaches.
4. What target indications are covered by this patent?
The patent possibly claims therapeutic use in cancer, autoimmune conditions, or infections, depending on the biological activity data disclosed in the specification.
5. Can the synthesis methods claimed be independently patented?
If the synthesis routes are novel, non-obvious, and sufficiently inventive, they can be separately patented in their own rights, offering an additional layer of protection.
References
- USPTO Patent Document: United States Patent 9,808,587, issued November 7, 2017.
- Related Patents and Literature: As cited within the landscape analysis.
- Regulatory Agencies: FDA records for approved drugs related to the patent’s compounds.
